Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24693296 | 1.00 | PTGDR2 (0.34) | PTGDR2SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL24693054 | 0.94 | HCRTR1 (0.34) | PTGDR2MEN1KMT2AKCNH2HCRTR1 | |
| SCHEMBL24693302 | 0.92 | SLC6A2 (0.35) | PTGDR2SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL24693055 | 0.91 | SLC6A2 (0.34) | PTGDR2SLC6A2SLC6A4SLC6A3HCRTR1 | |
| SCHEMBL24693053 | 0.91 | SLC6A2 (0.34) | PTGDR2SLC6A2SLC6A4SLC6A3HCRTR1 | |
| SCHEMBL24693333 | 0.91 | SLC6A2 (0.34) | PTGDR2SLC6A2SLC6A4SLC6A3HCRTR1 | |
| SCHEMBL24693077 | 0.89 | KCNH2 (0.36) | PTGDR2MEN1KMT2AKCNH2HCRTR1 | |
| SCHEMBL24693075 | 0.89 | KCNH2 (0.36) | PTGDR2MEN1KMT2AKCNH2HCRTR1 | |
| SCHEMBL24694378 | 0.87 | BRD3 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24694371 | 0.87 | BRD3 (0.33) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| WO-2022253167-A1 | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | PTGDR2 2406/4885SLC6A2 4878/4885SLC6A4 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.